---
symbol: "MRNA"
name: "Moderna"
date: 2026-10-07
change_pct: 4.117240278738221
direction: "up"
event_type: "contract_deal"
url: "https://perplo.app/why/MRNA/2026-10-07"
updated_at: 2026-10-07T21:06:37.986Z
---

# Why Moderna (MRNA) rose 4.12% on October 7, 2026

Moderna (MRNA) rose 4.12% on October 7, 2026 — Tempus therapy deal with Merck and Moderna lifts shares.

## What happened

Tempus AI announced an expanded therapy collaboration with Merck and Moderna, deepening a data and assay partnership that touches Moderna-linked programs. Moderna rose 3.3% on the news.

## Why it moved

A broader Tempus tie-up can widen how its assay and clinical data are used across Moderna's pipeline, which investors read as a path to future revenue from those programs.

## Why it matters

This fits the Healthcare & Biotech theme, where value is shifting toward companies that pair therapeutics with data and diagnostics to speed development and trial design.

## What would break the thesis

If the collaboration is narrow, non-exclusive, or carries no new commercial terms, the upside fades quickly. Investors should look for disclosed deal size, milestones, or revenue attached to Moderna-linked programs.

## Sources

- [Tempus expands collaboration with Merck and Moderna on therapy](https://www.investing.com/news/company-news/tempus-expands-collaboration-with-merck-and-moderna-on-therapy-93CH-4936660) — Investing.com

---

Trade MRNA perpetual futures 24/7 onchain: https://perplo.app/asset/MRNA